Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) Short Interest Up 151.6% in December

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) was the target of a large growth in short interest in the month of December. As of December 15th, there was short interest totalling 4,000,000 shares, a growth of 151.6% from the November 30th total of 1,590,000 shares. Currently, 2.1% of the shares of the stock are short sold. Based on an average daily trading volume, of 93,440,000 shares, the days-to-cover ratio is presently 0.0 days.

Tonix Pharmaceuticals Price Performance

TNXP stock traded down $0.03 during trading on Friday, reaching $0.34. 61,910,764 shares of the company were exchanged, compared to its average volume of 30,361,879. Tonix Pharmaceuticals has a 52-week low of $0.12 and a 52-week high of $14.08. The company has a debt-to-equity ratio of 0.07, a quick ratio of 2.81 and a current ratio of 3.33. The company has a market cap of $63.84 million, a P/E ratio of -0.01 and a beta of 2.23. The stock’s 50 day moving average price is $0.22 and its 200 day moving average price is $0.41.

Tonix Pharmaceuticals (NASDAQ:TNXP) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.23) earnings per share for the quarter, topping analysts’ consensus estimates of ($2.03) by $1.80. The business had revenue of $2.82 million for the quarter, compared to analysts’ expectations of $2.63 million. Tonix Pharmaceuticals had a negative return on equity of 163.95% and a negative net margin of 1,197.86%. As a group, analysts predict that Tonix Pharmaceuticals will post -17.63 earnings per share for the current fiscal year.

Analyst Ratings Changes

Separately, StockNews.com began coverage on Tonix Pharmaceuticals in a report on Monday. They set a “hold” rating on the stock.

About Tonix Pharmaceuticals

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.